GE HealthCare Technologies Inc.

Drug pipeline (38)

Asset	Stage	Revenue	Status
Calcium	approved	—	—
Cyanocobalamin	approved	—	—
CYANOCOBALAMIN CO-57	approved	—	—
CYANOCOBALAMIN CO-58	approved	—	—
Diatrizoate meglumine	approved	—	—

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (58)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT06398730	phase1	completed	2024-07-02	2026-02-19	GE Healthcare	A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers
NCT07472491	phase2_3	recruiting	2026-04-01	2027-11-30	GE Healthcare	A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients
NCT00565721	phase2	completed	2007-11-01	2011-10-01	GE Healthcare	A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
NCT00730964	phase4	completed	2008-05-01	2009-10-01	GE Healthcare	A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.
NCT00209391	phase3	completed	2003-09-01	2005-08-01	GE Healthcare	A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide

FDA applications (54)

Application

Type

Applicant

Products

ANDA 086505

ANDA

GE HEALTHCARE

ANDA 210016

ANDA

GE HEALTHCARE

ANDA 215955

ANDA

GE HEALTHCARE

ANDA 215957

ANDA

GE HEALTHCARE INC

NDA 008032

NDA

GE HEALTHCARE